Annenberg Center for Health Sciences
Perspectives on Selected Myasthenia Gravis Posters and Abstracts From AANEM
Myasthenia gravis, an autoimmune disease characterized by fluctuating muscle weakness, greatly impacts patients’ functioning and activities of daily living. Important treatment advances continue to be made to reduce patient burden of disease and overcome safety, efficacy, and other limitations of available therapies. Join Nicholas Silvestri, MD, as he reports on research results of some of these advances presented at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting.
Be sure to visit the podcast's website and support the creator: annenberg.net
Author
Annenberg Center for Health Sciences
Category
Podcast website
Latest episode
Nov 19, 2024
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
Long-Term Safety and Efficacy of Zilucoplan in Generalized Myasthenia Gravis 120-Week Interim Analysis of RAISE-XT 19.11.2024 2:53
Author: Howard, JF, et al. Overview Provided by Nicolas Silvestri, MD
Efficacy and Safety of Nipocalimab in Patients with Generalized Myasthenia Gravis: Topline Results from the Double-Blind, Placebo-Controlled, Randomized Phase 3 VIVACITY-MG3 Study 19.11.2024 3:26
Author: Strober J, et al. Overview Provided by Nicolas Silvestri, MD
Concomitant Corticosteroid Use with Ravulizumab in Adults with Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Phase 3 CHAMPION-MG Open-Label Extension Final Results 19.11.2024 3:25
Author: Nicolle M, et al. Overview Provided by Nicolas Silvestri, MD
Cyclic and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis Part A of ADAPT NXT 19.11.2024 3:14
Author: Habib AA, et al Overview Provided by Nicolas Silvestri, MD
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.